306 related articles for article (PubMed ID: 25791169)
41. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity.
Fass DM; Reis SA; Ghosh B; Hennig KM; Joseph NF; Zhao WN; Nieland TJ; Guan JS; Kuhnle CE; Tang W; Barker DD; Mazitschek R; Schreiber SL; Tsai LH; Haggarty SJ
Neuropharmacology; 2013 Jan; 64():81-96. PubMed ID: 22771460
[TBL] [Abstract][Full Text] [Related]
42. Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure.
Nural-Guvener H; Zakharova L; Feehery L; Sljukic S; Gaballa M
Int J Mol Sci; 2015 May; 16(5):11482-99. PubMed ID: 25997003
[TBL] [Abstract][Full Text] [Related]
43. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms.
Beier UH; Wang L; Han R; Akimova T; Liu Y; Hancock WW
Sci Signal; 2012 Jun; 5(229):ra45. PubMed ID: 22715468
[TBL] [Abstract][Full Text] [Related]
44. The Zinc-dependent HDACs: Non-histone Substrates and Catalytic Deacylation Beyond Deacetylation.
Zheng W
Mini Rev Med Chem; 2022; 22(19):2478-2485. PubMed ID: 35362374
[TBL] [Abstract][Full Text] [Related]
45. Small molecule inhibitors of zinc-dependent histone deacetylases.
Wagner FF; Weїwer M; Lewis MC; Holson EB
Neurotherapeutics; 2013 Oct; 10(4):589-604. PubMed ID: 24101253
[TBL] [Abstract][Full Text] [Related]
46. Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.
Godoy LD; Lucas JE; Bender AJ; Romanick SS; Ferguson BS
Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27981795
[TBL] [Abstract][Full Text] [Related]
47. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
Eom GH; Kook H
Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
[TBL] [Abstract][Full Text] [Related]
48. Isoform-selective histone deacetylase inhibitors.
Itoh Y; Suzuki T; Miyata N
Curr Pharm Des; 2008; 14(6):529-44. PubMed ID: 18336298
[TBL] [Abstract][Full Text] [Related]
49. Role of histone deacetylases in bone development and skeletal disorders.
Wang JS; Yoon SH; Wein MN
Bone; 2021 Feb; 143():115606. PubMed ID: 32829038
[TBL] [Abstract][Full Text] [Related]
50. The inhibitory effects of class I histone deacetylases on hippocampal neuroinflammatory regulation in aging mice with postoperative cognitive dysfunction.
Yang CX; Bao F; Zhong J; Zhang L; Deng LB; Sha Q; Jiang H
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):10194-10202. PubMed ID: 33090427
[TBL] [Abstract][Full Text] [Related]
51. Targeting histone deacetylases for heart diseases.
Jin G; Wang K; Zhao Y; Yuan S; He Z; Zhang J
Bioorg Chem; 2023 Sep; 138():106601. PubMed ID: 37224740
[TBL] [Abstract][Full Text] [Related]
52. The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.
Bassett SA; Barnett MP
Nutrients; 2014 Oct; 6(10):4273-301. PubMed ID: 25322459
[TBL] [Abstract][Full Text] [Related]
53. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing.
Trapp J; Jung M
Curr Drug Targets; 2006 Nov; 7(11):1553-60. PubMed ID: 17100594
[TBL] [Abstract][Full Text] [Related]
54. Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy.
Evans LW; Bender A; Burnett L; Godoy L; Shen Y; Staten D; Zhou T; Angermann JE; Ferguson BS
J Nutr Biochem; 2020 May; 79():108339. PubMed ID: 32007664
[TBL] [Abstract][Full Text] [Related]
55. Class I HDACs control a JIP1-dependent pathway for kinesin-microtubule binding in cardiomyocytes.
Blakeslee WW; Lin YH; Stratton MS; Tatman PD; Hu T; Ferguson BS; McKinsey TA
J Mol Cell Cardiol; 2017 Nov; 112():74-82. PubMed ID: 28886967
[TBL] [Abstract][Full Text] [Related]
56. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
57. HDAC-dependent ventricular remodeling.
Xie M; Hill JA
Trends Cardiovasc Med; 2013 Aug; 23(6):229-35. PubMed ID: 23499301
[TBL] [Abstract][Full Text] [Related]
58. HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis.
Renaud L; Harris LG; Mani SK; Kasiganesan H; Chou JC; Baicu CF; Van Laer A; Akerman AW; Stroud RE; Jones JA; Zile MR; Menick DR
Circ Heart Fail; 2015 Nov; 8(6):1094-104. PubMed ID: 26371176
[TBL] [Abstract][Full Text] [Related]
59. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy.
Oka S; Ago T; Kitazono T; Zablocki D; Sadoshima J
J Mol Med (Berl); 2009 Aug; 87(8):785-91. PubMed ID: 19424677
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic potential for HDAC inhibitors in the heart.
McKinsey TA
Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
